Albert / Wood Targets and Emerging Therapies for Schizophrenia

1. Auflage 2012
ISBN: 978-1-118-30940-7
Verlag: John Wiley & Sons
Format: EPUB
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 486 Seiten, E-Book

New and emerging directions in pharmaceutical research tobetter treat schizophrenia
Although the dopamine hypothesis has been the cornerstone ofschizophrenia therapeutics, it is clear that dopamine-basedapproaches do not treat all aspects of the disease. Moreover, manyschizophrenia patients fail to respond to current antipsychotics.Integrating chemistry, biology, and pharmacology, this bookexplores emerging directions in pharmaceutical research for drugtargeting and discovery in order to find more effective treatmentsfor schizophrenia, one of the most serious and widespreadpsychiatric diseases.
Targets and Emerging Therapies for Schizophrenia presentsthe basics of schizophrenia, drug targets for the disease, andpotential new drugs and therapeutics. It begins with a discussionof prevalence and etiology. Then, it describes therapies such asdopamine agonists and phosphodiesterase (PDE) inhibitors as well asgrowing research aimed at addressing untreated symptoms. Next, theauthors discuss receptor modulators, inhibitors, and targetingstrategies for drug discovery. Both the neurobiological andchemical aspects of all major pharmacological targets areexamined.
With contributions from an international team of pioneeringpharmaceutical researchers, this book compiles the currentknowledge in the field, setting the stage for new breakthroughs inthe treatment of schizophrenia. Targets and Emerging Therapiesfor Schizophrenia:
* Provides a comprehensive resource for neuro-drug discovery andthe development of molecular targets for schizophreniatreatment
* Draws from chemistry, biology, and pharmacology for moreeffective drug targeting and discovery
* Explores a wide range of receptors and molecular targets,including dopamine, PDEs, and neuropeptides
With Targets and Emerging Therapies for Schizophrenia astheir guide, drug discovery and development scientists have theinformation they need to advance their own research so that new,more effective treatments for schizophrenia will soon be areality.

Autoren/Hrsg.

Albert, Jeffrey S.

Wood, Michael W.

Inhaltsverzeichnis

Preface vii
Contributors xi
Introduction 1
Alan J. Cross
1 Dopaminergic Hypothesis of Schizophrenia: A HistoricalPerspective 5
Aurelija Jucaite and Svante Nyberg
2 Dopamine D2/D3 Partial Agonists as Antipsychotics 37
Philip G. Strange
3 D1/D5 Dopamine Agonists as Pharmacotherapy for Schizophrenia51
Kevin N. Boyd and Richard B. Mailman
4 Phosphodiesterase Inhibitors as a Novel Therapeutic Approachfor Schizophrenia 85
Judith A. Siuciak and William J. Pitts
5 Glutamatergic Synaptic Dysregulation in Schizophrenia115
Joseph T. Coyle, Alo Basu, and Michael Benneyworth
6 Metabotropic Glutamate 2/3 Receptor Agonists and PositiveAllosteric Modulators of Metabotropic Glutamate Receptor 2 as NovelAgents for the Treatment of Schizophrenia 143
Gerard J. Marek, Bruce J. Kinon, David L. McKinzie, Jeffrey M.Schkeryantz, and James A. Monn
7 AMPA Receptor Positive Modulators 187
John A. Morrow, John K.F. Maclean, and Craig Jamieson
8 Progress in the Exploration and Development of GlyT1Inhibitors for Schizophrenia 233
Jeffrey S. Albert and Michael W. Wood
9 Combined Dopamine D2 and 5-Hydroxytryptamine (5-HT)1A ReceptorStrategies for the Treatment of Schizophrenia: A Pharmacologicaland Chemical Perspective 255
Andrew C. McCreary, Roelof W. Feenstra, and Caitlin A.Jones
10 5-HT2C and 5-HT6 Receptor Targeted Emerging Approaches inSchizophrenia 273
Sharon Rosenzweig-Lipson, John Dunlop, Lee E. Schechter, ThomasA. Comery, Jonathan Gross, and Karen L. Marquis
11 The Cholinergic Hypothesis: An Introduction to the Hypothesisand a Short History 295
Joseph I. Friedman, Isabella Kanellopoulou, and VladanNovakovic
12 alpha7 Nicotinic Acetylcholine Receptors in the Treatment ofSchizophrenia 319
Mihály Hajós and Bruce N. Rogers
13 Muscarinic Acetylcholine Receptors as Novel Targets for theDevelopment of Therapeutics for Schizophrenia 355
Christian C. Felder, David L. McKinzie, Richard C. Thompson, andBin Liu
14 Will Modulation of Neuropeptide Receptors Produce the NextGeneration of Antipsychotic Drugs? A Focus on the Neurokinin andNeurotensin Systems 381
Lee A. Dawson, Paul W. Smith, and Jeannette M. Watson
15 GABA and Schizophrenia 425
John H. Kehne and George D. Maynard
Index 469

Über Autor(innen)

JEFFREY S. ALBERT, PhD, is a Project Leader and Head ofLead Generation Chemistry in AstraZeneca's neuroscience department.He has authored or coauthored more than forty publications, mostlyfocusing on novel therapeutic targets involved in depression,schizophrenia, and Alzheimer's disease and on the development andapplication of fragment-based lead generation methodologies.
MICHAEL W. WOOD, PhD, is an External CollaborationsDirector in AstraZeneca's neuroscience unit where he is responsiblefor coordinating research to deliver novel therapeutics targetingschizophrenia as well as other neuroscience treatments. He has beenfocused on neuroscience drug discovery research for fifteenyears.